Biodexa Pharmaceuticals plc Am short interest was 89.4% of the float on October 15th, according to new data we received from Benzinga. Short interest totaled 919,936 shares, which was an increase of 4,905.09% from September 30th.
It is estimated that it would take 1.0 days for short sellers to buy back their shares, with current trading volumes.
Biodexa Pharmaceuticals plc Am Hedge Fund Activity
We have seen 1 institutional investors add shares of Biodexa Pharmaceuticals plc Am stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SABBY MANAGEMENT, LLC removed 51,494 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $149,847
- ARMISTICE CAPITAL, LLC removed 4,695 shares (-24.1%) from their portfolio in Q2 2026, for an estimated $13,662
- GAMMA INVESTING LLC removed 1,203 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $789
- RHUMBLINE ADVISERS removed 16 shares (-84.2%) from their portfolio in Q2 2026, for an estimated $46
- SBI SECURITIES CO., LTD. removed 10 shares (-34.5%) from their portfolio in Q3 2026, for an estimated $6
- HILTON HEAD CAPITAL PARTNERS, LLC removed 6 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $3
- CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD added 4 shares (+400.0%) to their portfolio in Q2 2026, for an estimated $11
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
